Novel use of tranexamic acid to reduce the need for Nasal Packing in Epistaxis (NoPac) randomised controlled trial: research protocol.
Administration, Intranasal
Administration, Topical
Antifibrinolytic Agents
/ administration & dosage
Double-Blind Method
Emergency Service, Hospital
Endotamponade
/ methods
Epistaxis
/ drug therapy
Humans
Multicenter Studies as Topic
Randomized Controlled Trials as Topic
Tranexamic Acid
/ administration & dosage
Treatment Outcome
emergency
epistaxis
intranasal
packing
topical
tranexamic acid
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
15 02 2019
15 02 2019
Historique:
entrez:
18
2
2019
pubmed:
18
2
2019
medline:
26
3
2020
Statut:
epublish
Résumé
Patients presenting to emergency departments (EDs) with epistaxis uncontrolled by subsequent simple first aid measures or application of topical vasoconstrictors will typically undergo anterior nasal packing. Packing is effective, but can be extremely painful and unpleasant and patients usually need hospital admission. Tranexamic acid (TXA) is a cheap, safe, readily available antifibrinolytic agent known to be beneficial in a variety of clinical settings where uncontrolled bleeding may be a problem. Anecdotal evidence suggests that topical TXA may be of value in persistent epistaxis; however, further evaluation is required. This is a multicentre, double-blind, parallel group, randomised, controlled trial comparing the use of topical intranasal TXA with indistinguishable placebo in adults presenting to UK EDs with persistent atraumatic epistaxis. Follow-up is at 1 week by structured telephone review. The primary outcome measure is the subsequent need for anterior nasal packing in the ED. Key secondary outcomes include the need for hospital admission, blood transfusion and/or further treatment for epistaxis during the index ED attendance. Recruiting 450 patients will provide 90% power to demonstrate an absolute reduction in packing rate from 95% to 85%. An improvement of this magnitude would be of significant benefit to patients and healthcare providers and justify a change to standard practice. Given the low cost of TXA and its short administration time, a full economic evaluation is not being undertaken. The study has been approved by the South West-Bristol Research Ethics Committee (reference 17/SW/0010). We aim to publish the findings in a high impact, international peer-reviewed journal. Results will also be shared with the Hereditary Haemorrhagic Telangiectasia foundation and telangiectasia UK for dissemination through appropriate related forums. ISRCTN34153772 and EudraCT No: 2016-001530-10.
Identifiants
pubmed: 30772866
pii: bmjopen-2018-026882
doi: 10.1136/bmjopen-2018-026882
pmc: PMC6398761
doi:
Substances chimiques
Antifibrinolytic Agents
0
Tranexamic Acid
6T84R30KC1
Banques de données
ISRCTN
['ISRCTN34153772']
EudraCT
['EudraCT 2016-001530-10']
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e026882Subventions
Organisme : Department of Health
ID : PB-PG-0215-36142
Pays : United Kingdom
Organisme : Department of Health
ID : PDF-2012-05-193
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Ann Otol Rhinol Laryngol. 1995 Sep;104(9 Pt 1):704-6
pubmed: 7661519
J Laryngol Otol. 1996 Jun;110(6):543-6
pubmed: 8763373
Med Clin North Am. 1999 Jan;83(1):43-56
pubmed: 9927959
Lancet. 2011 Mar 26;377(9771):1096-101, 1101.e1-2
pubmed: 21439633
Cochrane Database Syst Rev. 2013 Jul 23;(7):CD010562
pubmed: 23881695
Arch Emerg Med. 1989 Sep;6(3):233
pubmed: 2789592
Int J Otolaryngol. 2015;2015:263987
pubmed: 26351457
Emerg Med J. 2014 May;31(5):436-7
pubmed: 24846097
Trials. 2014 Nov 19;15:450
pubmed: 25409738
Br J Surg. 2013 Sep;100(10):1271-9
pubmed: 23839785
Postgrad Med J. 2005 May;81(955):309-14
pubmed: 15879044
ORL J Otorhinolaryngol Relat Spec. 1995 Jul-Aug;57(4):207-9
pubmed: 7478455
Clin Cardiol. 1986 Sep;9(9):423-8
pubmed: 3093125
Am J Emerg Med. 2013 Sep;31(9):1389-92
pubmed: 23911102